Rank: 19 | Score: 80/100
p-Tau217 Adaptive Dosing Protocol is a biomarker-guided therapeutic strategy that uses longitudinal p-tau217 (phosphorylated tau at threonine 217) measurements to dynamically titrate anti-tau immunotherapy dosing. This approach addresses a critical challenge in tau-targeted therapies: the need for personalized dosing based on individual pathological burden and treatment response.
Phosphorylated tau at threonine 217 (p-tau217) has emerged as one of the most promising fluid biomarkers for Alzheimer's disease:
- Specificity: p-tau217 shows high specificity for Alzheimer's disease compared to other neurodegenerative conditions
- Sensitivity: Detectable in cerebrospinal fluid (CSF) and plasma years before clinical symptoms
- Correlation: Strong correlation with cortical tau burden as measured by PET
- Dynamic range: Levels change in response to disease progression and therapeutic intervention
Current anti-tau immunotherapy approaches use fixed dosing schedules that fail to account for:
- Individual variation in tau pathology burden
- Differential response rates to treatment
- Potential for overtreatment in early-stage patients
- Undertreatment in rapid progressors
An adaptive dosing protocol based on p-tau217 trajectories can optimize:
- Efficacy: Maintain therapeutic benefit while avoiding underdosing
- Safety: Minimize dose-related adverse events
- Cost: Reduce unnecessary drug exposure
- Precision: Enable personalized treatment algorithms
| Dimension |
Score |
Rationale |
| Novelty |
8 |
Adaptive dosing protocols for tau immunotherapy are in early development; p-tau217 as dynamic biomarker is emerging |
| Mechanistic Rationale |
9 |
Strong biological basis linking p-tau217 to treatment response |
| Root-Cause Coverage |
8 |
Addresses tau pathology but uses biomarker rather than direct mechanism |
| Delivery Feasibility |
9 |
Uses existing anti-tau antibodies; only adds biomarker monitoring |
| Safety Plausibility |
8 |
Adaptive dosing could improve safety by reducing unnecessary exposure |
| Combinability |
9 |
Highly compatible with other anti-tau, anti-amyloid, or neuroprotective approaches |
| Biomarker Availability |
9 |
p-tau217 assays are commercially available and validated |
| De-risking Path |
8 |
Clear regulatory pathway using existing antibody frameworks |
| Multi-disease Potential |
7 |
Primarily AD-focused; some applicability to primary tauopathies |
| Patient Impact |
8 |
Personalized dosing improves outcomes and reduces adverse events |
| Total |
81/100 |
Calculated from 10 dimensions |
- Establish baseline p-tau217 levels at screening
- Confirm amyloid and/or tau positivity per inclusion criteria
- Define individual "responder" profile
- Standard induction dosing (e.g., loading dose series)
- p-tau217 sampling at weeks 4, 8, 12, 16
- Responder algorithm: If p-tau217 decline >30% from baseline, maintain current dose
- Partial responder: If decline 15-30%, consider dose escalation
- Non-responder: If decline <15%, re-evaluate or add combination therapy
¶ Phase 4: Maintenance
- Ongoing p-tau217 monitoring every 3-6 months
- Dose adjustments based on sustained response or relapse
- Use established anti-tau antibodies (e.g., gosuranemab, tilavonemab, semorinemab) as platform
- Partner with p-tau217 assay providers (Roche, Fujirebio, ALZpath)
- Develop point-of-care plasma p-tau217 for decentralized monitoring
- Start with Phase 2 adaptive dosing substudy in ongoing trials
- Use umbrella trial design to test multiple adaptive algorithms
- Engage FDA/BMH early on biomarker-driven endpoints
- Position as companion diagnostic + therapeutic combo
- Value proposition: improved efficacy + reduced adverse events = better payor economics
¶ Risks and Mitigation
-
p-tau217 assay standardization: Different assays (Roche, Lilly, Simoa) use different epitopes and yield different values
- Mitigation: Standardize to single assay for clinical use; develop conversion algorithms
-
Adaptive dosing overtreatment: Frequent dose adjustments based on biomarker may lead to over-treatment
- Mitigation: Set clear minimum/maximum dose boundaries; require sustained elevation for escalation
-
Drug-biomarker interaction: Anti-amyloid drugs may affect p-tau217 independently of clinical effect
- Mitigation: Use multiple tau biomarkers (p-tau181, p-tau231) for validation
-
Patient burden: Frequent biomarker sampling (CSF or blood) may reduce compliance
- Mitigation: Develop less invasive sampling methods; use dried blood spot testing
-
Clinical validation: P-tau217 as adaptive dosing biomarker needs prospective validation
- Mitigation: Include biomarker validation endpoints in Phase 3 trials
| Phase |
Duration |
Milestones |
| Assay Standardization |
6 months |
Single-platform validation |
| Phase 2 Trial |
18 months |
Biomarker-guided dosing |
| Phase 3 Trial |
24 months |
Registrational trial |
| Phase |
Estimated Cost |
Notes |
| Assay Development |
$2-3M |
Standardization |
| Phase 2 |
$15-20M |
Adaptive design |
| Phase 3 |
$30-40M |
Registration |
| Total |
$47-63M |
End-to-end |
- University of Gothenburg — Henrik Zetterberg
- Washington University — Randall Bateman
- Mayo Clinic — Michelle Mielke
- Roche — Elecsys p-tau217
- Eli Lilly — p-tau217 assays
- Quanterix — Simoa platform
- Biogen — AD pipeline
- p-Tau217 assay validation: Run head-to-head comparison of plasma p-tau217 from multiple vendors (Roche, Fujirebio, ALZpath, Quanterix) in 200+ AD patient samples to establish assay interchangeability and correlation with CSF p-tau217
- Adaptive algorithm development: Using historical data from failed anti-tau trials (gosuranemab, tilavonemab, semorinemab), develop machine learning models to predict responders based on baseline p-tau217, age, and APOE status
- Proof-of-concept in animal models: Test adaptive dosing in tau transgenic mice (P301S, 3xTg-AD) with serial plasma p-tau217 sampling to correlate with brain tau PET
- Phase 2 adaptive substudy: Propose 48-week adaptive dosing substudy within existing anti-tau trial (e.g., tau Axon registry), comparing standard fixed dosing vs. p-tau217-guided titration
- Enrichment strategy: Use baseline p-tau217 >60 pg/mL as enrollment criterion to ensure adequate pathological burden
- Endpoint selection: Primary endpoint = change in global cognition (ADAS-Cog13) at week 48; key secondary = change in plasma p-tau217, tau PET SUVr
- Adaptive design features: Pre-specified interim analysis at week 24 for sample size re-estimation or dose-escalation trigger
- Anti-tau antibody developers:
- Eli Lilly (semorimenab) — already has tau pipeline
- Biogen/AstraZeneca (gosuranemab) — partnered on tau
- AbbVie — seeking differentiation in crowded space
- Diagnostic partners:
- Roche Diagnostics — Neurop sekter p-tau217 platform
- Fujirebio — Lumipulse CSF p-tau217
- C2N Diagnostics — PrecivityAD blood test
- Digital health: AiCare, Linus Health for integrated biomarker tracking
- NIH NIA:
- R21 (Exploratory/Developmental): "p-Tau217-guided adaptive anti-tau dosing in early AD" (~=K over 2 years)
- U01 (Phase 2 trial planning): "Adaptive Dosing Platform for Tau Immunotherapy" (~M over 3 years)
- SBIR/STTR (with diagnostic partner): Companion diagnostic development
- Foundations:
- BrightFocus Foundation — A2022015N (AD biomarker trials)
- Alzheimer's Association — Part the Cloud (Phase 1/2 clinical trials)
- Michael J. Fox Foundation — therapeutic biomarker studies
- International:
- EU Joint Programme — Neurodegenerative Disease Research (JPND)
- UK Dementia Research Institute
Cost: $2.5-4M
| Milestone |
Timeline |
Cost |
Risk |
| p-Tau217 multi-vendor comparison study |
Months 1-9 |
$800K |
Low |
| Adaptive algorithm ML model development |
Months 6-15 |
$1.2M |
Medium |
| Pre-IND meeting with FDA |
Month 12 |
$200K |
Low |
| IND-enabling pharmacology summary |
Months 12-18 |
$500K |
Low |
Key Risks:
- Assay variability could require additional validation (mitigation: include 3+ vendors)
- Algorithm accuracy may need iteration (mitigation: iterative training with real trial data)
Cost: $8-15M
| Milestone |
Timeline |
Cost |
Risk |
| Site initiation (15-20 sites US/EU) |
Months 15-18 |
$1.5M |
Low |
| Patient enrollment (n=200 adaptive) |
Months 18-30 |
$6M |
Medium |
| Interim analysis (week 48) |
Month 30 |
$500K |
Medium |
| Final analysis (week 96) |
Month 36 |
$1M |
Low |
Key Risks:
- Enrollment could miss targets (mitigation: inclusion of international sites)
- Adaptive algorithm may need adjustment (mitigation: pre-specified adaptation rules)
Cost: $35-55M
| Milestone |
Timeline |
Cost |
Risk |
| Phase 3 protocol finalization |
Months 30-33 |
$2M |
Low |
| Global enrollment (n=800-1000) |
Months 33-48 |
$25M |
Medium |
| Phase 3 readout |
Month 56 |
$5M |
Medium |
| NDA/MAA filing and approval |
Months 56-60 |
$8M |
Low |
Key Risks:
- Phase 2/3 regulatory feedback may require design changes
- Competition from standard-of-care anti-tau antibodies
| Scenario |
Probability |
Cost Impact |
| Best case (accelerated approval) |
15% |
$35M |
| Base case |
50% |
$55M |
| Slow enrollment + one protocol amendment |
25% |
$75M |
| Program pivot (new target) |
10% |
+$20M |
- US: Mayo Clinic (tau biomarker expertise), UC Irvine (ADRC), Washington University (DIAN)
- EU: Karolinska Institutet (Sweden), University of Cambridge (UK), Charité Berlin (Germany)
- Industry Partners: Thermo Fisher (assay manufacturing), WuXi AppTec (CRO)
| Gate |
Criteria |
Go/No-Go |
| Phase 1→2 |
Positive assay validation + FDA feedback |
Go if assay CV <15% |
| Phase 2→3 |
Week 48 p-Tau217 correlation with cognition |
Go if r > 0.4, p < 0.01 |
| Registration |
Phase 3 interim shows significance |
Go if p < 0.025 |
- Assay validation protocol: Finalize p-Tau217 assay validation plan with 3 certified labs (Mayo, USC, Copenhagen). Define CV acceptance criteria (<15%).
- Regulatory pre-pre-IND meeting: Schedule informal FDA meeting to discuss adaptive dosing framework and biomarker-driven design.
- Site feasibility assessment: Evaluate 10 potential Phase 1 sites for early-phase biomarker endpoint experience.
- Assay validation study: Complete inter-assay and intra-assay CV testing across 3 labs using standardized plasma samples.
- Phase 1 protocol finalization: Design adaptive dosing Phase 1 with biomarker endpoints (p-Tau217, p-Tau181, total tau).
- Patient recruitment materials: Develop genetics-first recruitment strategy for APOE4 carriers and sporadic AD.
- Establish p-Tau217 cutoff thresholds for treatment response (not just diagnosis)
- Validate correlation between plasma p-Tau217 and CSF p-Tau217 in treatment-naive subjects
- Assess assay performance in diverse ethnic populations
- Academic: Join DIAN-TU consortium for adaptive trial design expertise
- Pharma: Partner with tau immunotherapy companies ( Lilly, Roche) for combination trial potential
- Diagnostic: Work with ALZpath and Quanterix on assay standardization
| Dimension |
Score |
Rationale |
| Novelty |
7/10/10 |
p-tau217 as biomarker is breakthrough; adaptive dosing is innovative |
| Mechanistic Rationale |
6/10/10 |
Uses biomarker for treatment guidance; addresses pharmacokinetics, not pathology |
| Addresses Root Cause |
6/10/10 |
Optimizes drug delivery; indirect effect on disease modification |
| Delivery Feasibility |
7/10/10 |
Same as standard dosing; biomarker drives timing |
| Safety Plausibility |
7/10/10 |
Enhanced safety monitoring; biomarker-guided dose adjustment |
| Combinability |
7/10/10 |
Compatible with any disease-modifying therapy |
| Biomarker Availability |
9/10/10 |
p-tau217 is highly validated; accessible via blood test |
| De-risking Path |
8/10/10 |
Platform approach; can be applied to multiple drugs |
| Multi-disease Potential |
7/10/10 |
Broad applicability across AD therapeutics |
| Patient Impact |
8/10/10 |
Could significantly improve therapeutic outcomes and reduce adverse events |
| Total |
72/100 |
|